# Celanese Corporation (CE) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/CE/thesis · /stocks/CE/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: CE
step: "04"
title: Financial Snapshot — Celanese Corporation
created: 2026-05-29
---

### Step 04: Financial Snapshot

#### Income Statement Summary

| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|--------|--------|--------|--------|---------|
| Revenue ($M) | $8,539 | $11,665 | $10,282 | ~$9,500-10,000 |
| Gross Profit ($M) | ~$2,600 | ~$3,200 | ~$2,400 | ~$2,100-2,300 |
| Gross Margin (%) | ~30.5% | ~27.4% | ~23.3% | ~22-24% |
| Adj. EBITDA ($M) | ~$2,200 | ~$2,500 | ~$2,050 | ~$1,700-1,900 |
| Adj. EBITDA Margin (%) | ~25.8% | ~21.4% | ~19.9% | ~18-20% |
| Adj. EBIT ($M) | ~$1,900 | ~$2,100 | ~$1,600 | ~$1,200-1,400 |
| Net Income (GAAP, $M) | ~$880 | ~$950 | ~$300-350 | ~$200-400 |
| Adj. EPS ($) | ~$11-12 | ~$13-14 | ~$9-10 | ~$7-9 |
| D&A ($M) | ~$300 | ~$400 | ~$450 | ~$450-480 |

Note: FY2022 includes partial-year M&M contribution (~2 months) and significant M&M acquisition-related costs (interest, deal fees). FY2023-2024 reflect full-year M&M burden but also a severe destocking cycle and pricing headwinds in both segments. GAAP net income is heavily impacted by acquisition-related amortization (~$500-600M/year for M&M intangibles).

#### Revenue Trend Analysis

**FY2021:** Celanese's best pre-M&M year. Acetyl chain benefited from tight global supply, high acetic acid pricing. EM volumes strong as auto production recovered from COVID-19 lows. Revenue grew from ~$5.6B (2020) to $8.5B.

**FY2022:** M&M closes November 2022, adding ~$500-600M revenue in the final two months. Full-year revenue peaks at $11.7B. However, headwinds were already emerging — global chemical destocking began in mid-2022 as post-COVID inventory building reversed, and acetyl pricing peaked.

**FY2023:** Revenue compresses to ~$10.3B despite a full year of M&M. Volume and pricing headwinds in both segments offset the added M&M scale. European weakness, China softness, and automotive destocking all weighed simultaneously. EBITDA margins compressed to ~20% from a ~25%+ peak.

**FY2024:** Continued revenue pressure. Auto production weakness, particularly in Europe (VW/Stellantis production cuts). Some acetyl pricing recovery on China demand, but below cycle levels. Management guiding for gradual recovery in H2 2024 and into 2025.

#### Margin Analysis

##### Gross Margin Drivers
Celanese's gross margins are sensitive to:
1. **Feedstock spreads (Acetyls):** Methanol and CO costs vs. acetic acid/VAM selling prices. When spreads compress (rising feedstocks + falling acid prices), gross margins contract sharply.
2. **Product mix (EM):** Higher-value LCP/PPS formulations carry 30-40% gross margins; commodity nylon is lower.
3. **Utilization rates:** High fixed-cost operations mean volume leverage is significant. 10% volume decline can compress EBIT by 15-20%.
4. **M&M Integration costs:** Temporary margin headwind from plant rationalization, workforce integration, and supply chain transition.

##### Adjusted EBITDA Margin Bridge
| Factor | FY2021 → FY2023 Impact |
|--------|------------------------|
| Volume/mix decline | ~(200-250) bps |
| Price/spread compression | ~(300-400) bps |
| M&M integration costs | ~(100-150) bps |
| SG&A leverage (M&M scale) | +50-100 bps |
| Synergy capture | +100-150 bps |
| **Net EBITDA margin compression** | **~(500-600) bps** |

#### Key P&L Metrics (Most Recent Reported — Approximated FY2023)

| Metric | Value | Commentary |
|--------|-------|-----------|
| Revenue | $10.28B | -11.9% YoY |
| Engineered Materials Revenue | ~$5.5B | Full year M&M; down ~10% on volume/price |
| Acetyl Chain Revenue | ~$4.75B | Down ~13% on pricing normalization |
| Adjusted EBITDA | ~$2.05B | ~20% margin; compressed vs. ~25%+ peak |
| Adj. EBIT | ~$1.55B | ~15% margin |
| Interest Expense | ~$600-650M | High due to ~$11B gross debt |
| GAAP Net Income | ~$300-350M | Impacted by M&M amortization |
| Adj. Net Income | ~$1.0-1.1B | Excluding M&M amortization and deal costs |
| CapEx | ~$450-500M | ~4-5% of revenue; elevated for M&M integration |
| Free Cash Flow | ~$700-900M | Post-CapEx; primary deleveraging tool |

#### GAAP vs. Adjusted Reconciliation

The gap between GAAP and adjusted metrics is significant for Celanese, primarily due to:

1. **M&M Acquisition Amortization:** ~$500-600M/year of non-cash amortization from intangible assets (customer relationships, trademarks, technology) acquired in the DuPont M&M deal. This will step down gradually over the useful lives (typically 10-20 years for customer relationships).

2. **Restructuring Charges:** Ongoing plant rationalization and workforce restructuring associated with M&M integration.

3. **Acquisition-Related Costs:** One-time deal fees, integration consulting, and financing costs.

Adjusted EPS significantly exceeds GAAP EPS (often 2-3x) because the amortization charge is excluded from adjusted. This is standard practice in the chemical industry for transformative M&A but warrants monitoring as a cash return on invested capital question.

#### Profitability vs. Chemical Peers

| Company | EBITDA Margin | ROIC | Leverage |
|---------|--------------|------|---------|
| Celanese | ~20% | ~8-10% (post-M&M) | ~5.5x Net Debt/EBITDA |
| Eastman Chemical | ~22-24% | ~12-14% | ~3x |
| Huntsman | ~10-12% | ~8-10% | ~2-3x |
| Avient | ~18-20% | ~10-12% | ~4x |
| Specialty Chemicals Avg | ~18-22% | ~10-14% | ~2.5-3x |

Celanese's margins are competitive but its leverage ratio (>5x post-M&M) is an outlier in the specialty chemicals space, creating both risk and potential for significant equity upside as deleveraging occurs.

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/CE/fundamental

## Navigation

- Overview: /stocks/CE
- Financials (this page): /stocks/CE/financials
- Thesis: /stocks/CE/thesis
- Investment Memo: /stocks/CE/memo
- Coverage universe: /stocks